November 18th 2024
More than half of US adults—approximately 137 million—are candidates for semaglutide based on diabetes, weight management, or cardiovascular prevention indications.
November 16th 2024
Diabetes Dialogue: Updates in Inpatient Management of Diabetes, with Jane Jeffrie Seley, DNP, MPH
December 13th 2022In this episode of Diabetes Dialogue, Jane Jeffrie Seley, DNP, MPH, a member of the writing committee for the ADA's Standards of Care in Diabetes—2023, joins the podcast to discuss pertinent updates in the sections of the document discussing inpatient management of diabetes within the document.
Empagliflozin Proves Benefit in Pediatric Type 2 Diabetes in Phase 3 DINAMO Trial
December 7th 2022Eli Lilly and Company and Boehringer Ingelheim announced their SGLT2 inhibitor, empagliflozin, was associated with statistically significant reductions in HbA1c relative to placebo therapy among a population of pediatric patients with type 2 diabetes in the DINAMO trial.
Co-Occuring Gestational Diabetes, Hypertension Linked with Doubling of Future Cardiovascular Risk
November 28th 2022An analysis of more than 800k women in Canada provides insight into the apparent increase in risk of incident cardiovascular disease associated with co-occurrence of gestational diabetes and gestational hypertensive disorders in pregnant women.
Universal Screening for Adults 40-70 Years Old Could Identify Most Diabetes Cases 2 Years Earlier
November 23rd 2022Using data from the UK Biobank study, a team of investigators from the University of Exeter determined undiagnosed cases of type 2 diabetes could be identified more than 2 years earlier if universal screening programs were implemented for middle-aged adults.
European Study Links Antibiotic Exposure to Increased Risk of Type 2 Diabetes Later in Life
November 22nd 2022An analysis of data from a pair of studies examining cardiovascular risk in individuals from countries in Europe provides insight into an apparent increase in the likelihood of developing type 2 diabetes among people with a history of exposure to antibiotics.
People with Type 2 Diabetes at Greater Risk of Having Advanced Stage Cancer at Time of Diagnosis
November 19th 2022An analysis of data from the EPIC study provides insight into an apparent increase in risk of having an advanced stage cancer at time of diagnosis for patients with cardiometabolic diseases compared to their counterparts without cardiometabolic diseases.
Diabetes Dialogue: What Teplizumab Means for Type 1 Diabetes
November 17th 2022In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.
Teplizumab Receives FDA Approval for Delaying Type 1 Diabetes
November 17th 2022On November 17, the US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.
Diabetes Dialogue: Obesity Updates, with Lydia Alexander, MD
November 14th 2022In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.
Diabetes' Changing Role in Cardiovascular Disease Management, with Diana Isaacs, PharmD
November 7th 2022Following a session examining the application of the latest iterations of cardiometabolic health guidelines, Diana Isaacs, PharmD, discusses how the evolving role of diabetes, and recognition of this role, in cardiovascular disease is reflected at the American Heart Association 2022 Scientific Sessions.